Associated Papers
Canonical microRNA loss drives tumor development implicating therapeutic efficacy of enoxacin in angiosarcoma.
Liu B et al.
Rna (new York, N.y.), 2026
Tracing the molecular route to progression in miRNA-biogenesis-defective thyroid lesions.
Chong AS et al.
Jci Insight, 2026
Novel susceptibility genes for non-NF2-/LZTR1-/SMARCB1-related hereditary schwannomatosis.
Nogué C et al.
Familial Cancer, 2025
Progression of Follicular Thyroid Carcinomas to Anaplastic Thyroid Carcinomas: Molecular and Clinicopathologic Characteristics with Comparison to Papillary Thyroid Carcinoma-Derived Anaplastic Thyroid Carcinomas.
Odate T et al.
Endocrine Pathology, 2025
Assessing Microprocessor complex mutations with a Microsensor system.
Bao S et al.
Rna (new York, N.y.), 2025
Distinct pathways for genetic and epigenetic predisposition in familial and bilateral Wilms tumor.
Wegert J et al.
Genome Medicine, 2025
Somatic copy number deletion of chromosome 22q in papillary thyroid carcinoma.
Lee OW et al.
European Thyroid Journal, 2025
Wilms tumor primary cultures capture phenotypic heterogeneity and facilitate preclinical screening.
Götz L et al.
Translational Oncology, 2025
MicroRNA regulator gene mutations in thyroid follicular nodular disease and thyroid cancer: does it all come down to timing?
Condello V et al.
European Thyroid Journal, 2024
Prevalence, Molecular Landscape, and Clinical Impact of DICER1 and DGCR8 Mutated Follicular-Patterned Thyroid Nodules.
Condello V et al.
The Journal of Clinical Endocrinology and Metabolism, 2024
Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children's Oncology Group AREN18B5-Q.
Murphy AJ et al.
Nature Communications, 2023
Genomics-Driven Precision Medicine in Pediatric Solid Tumors.
Suthapot P et al.
Cancers, 2023
DGCR8 Microprocessor Subunit Mutation and Expression Deregulation in Thyroid Lesions.
Rodrigues L et al.
International Journal of Molecular Sciences, 2022
Screening of potential novel candidate genes in schwannomatosis patients.
Perez-Becerril C et al.
Human Mutation, 2022
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.
Plotkin SR et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2022
The DGCR8 E518K mutation found in Wilms tumors leads to a partial miRNA processing defect that alters gene expression patterns and biological processes.
Vardapour R et al.
Carcinogenesis, 2022
Whole-genome Sequencing of Follicular Thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8.
Paulsson JO et al.
The Journal of Clinical Endocrinology and Metabolism, 2021
Pathogenic noncoding variants in the neurofibromatosis and schwannomatosis predisposition genes.
Perez-Becerril C et al.
Human Mutation, 2021
A pan-cancer atlas of somatic mutations in miRNA biogenesis genes.
Galka-Marciniak P et al.
Nucleic Acids Research, 2021
Regulatory Mechanism of MicroRNA Expression in Cancer.
Ali Syeda Z et al.
International Journal of Molecular Sciences, 2020
DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis.
Rivera B et al.
The Journal of Clinical Investigation, 2020
Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor.
Murphy AJ et al.
Nature Communications, 2019
DICER1 somatic mutations strongly impair miRNA processing even in benign thyroid lesions.
Poma AM et al.
Oncotarget, 2019
The genetic factors contributing to the development of Wilm's tumor and their clinical utility in its diagnosis and prognosis.
Bahrami A et al.
Journal of Cellular Physiology, 2018
A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.
Gadd S et al.
Nature Genetics, 2017
MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours.
Perlman EJ et al.
Nature Communications, 2015
Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors.
Walz AL et al.
Cancer Cell, 2015
Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors.
Wegert J et al.
Cancer Cell, 2015
Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour.
Torrezan GT et al.
Nature Communications, 2014
Dysregulation of microRNA biogenesis machinery in cancer.
Hata A et al.
Critical Reviews in Biochemistry and Molecular Biology, 0